Altimmune ALT
NASDAQ ALT
$2.76 -0.10 (-3.50%)
At close: Oct 1, 2026 · 4:00 PM EDT

Altimmune (ALT) Non-Current Deffered Revenue (2016 - 2018)

Updated

Altimmune (ALT) reported Non-Current Deffered Revenue of $144,838 for Q3 2018, down 12.0% from $164,609 a year earlier and down 3.3% from the prior quarter.

Analysis

Altimmune (ALT) Non-Current Deffered Revenue (2016 - 2018) Analysis & Trends

At the end of FY2017, Altimmune posted Non-Current Deffered Revenue of $159,671, down 11.0% from FY2016.

  • By year, Non-Current Deffered Revenue came in at $179,424 in FY2016.
  • Per Business Quant data, the three quarters before Q3 2018 came in at $149,785 (Q2 2018), $154,733 (Q1 2018) and $159,671 (Q4 2017).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Deffered Revenue (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn -
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn -
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn -
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn -
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn -
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn -
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn -
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn -
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn -
10 Altimmune 556.20 Mn 556.20 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2018 144,838.00
Jun 30, 2018 149,785.00
Mar 31, 2018 154,733.00
Dec 31, 2017 159,671.00
Sep 30, 2017 164,609.00
Jun 30, 2017 169,547.00
Dec 31, 2016 179,424.00
API Access

Altimmune Non-Current Deffered Revenue API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=non-current-deffered-revenue&ticker=ALT&period=max&api_key=YOUR_API_KEY